MPZ

Summary

MPZ (myelin protein zero, HGNC:7225) is a protein-coding gene on chromosome 1q23.3, encoding Myelin protein P0 (P25189). Is an adhesion molecule necessary for normal myelination in the peripheral nervous system.

This gene is specifically expressed in Schwann cells of the peripheral nervous system and encodes a type I transmembrane glycoprotein that is a major structural protein of the peripheral myelin sheath. The encoded protein contains a large hydrophobic extracellular domain and a smaller basic intracellular domain, which are essential for the formation and stabilization of the multilamellar structure of the compact myelin. Mutations in this gene are associated with autosomal dominant form of Charcot-Marie-Tooth disease type 1 (CMT1B) and other polyneuropathies, such as Dejerine-Sottas syndrome (DSS) and congenital hypomyelinating neuropathy (CHN). A recent study showed that two isoforms are produced from the same mRNA by use of alternative in-frame translation termination codons via a stop codon readthrough mechanism.

Source: NCBI Gene 4359 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Charcot-Marie-Tooth disease (Definitive, ClinGen) — +7 more curated relationships
• GWAS associations: 2
• Clinical variants (ClinVar): 720 total — 106 pathogenic, 57 likely-pathogenic
• Phenotypes (HPO): 93
• MANE Select transcript: NM_000530

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7225
Approved symbol	MPZ
Name	myelin protein zero
Location	1q23.3
Locus type	gene with protein product
Status	Approved
Aliases	HMSNIB, CMT2I, CMT2J, P0
Ensembl gene	ENSG00000158887
Ensembl biotype	protein_coding
OMIM	159440
Entrez	4359

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 4 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000463290, ENST00000476410, ENST00000488271, ENST00000526189, ENST00000533357, ENST00000672287, ENST00000672602

RefSeq mRNA: 2 — MANE Select: NM_000530 NM_000530, NM_001315491

CCDS: CCDS1229, CCDS91087

Canonical transcript exons

ENST00000533357 — 6 exons

Exon	Start	End
ENSE00001041809	161307258	161307424
ENSE00001313871	161309839	161309968
ENSE00001414908	161304735	161305977
ENSE00003615032	161306329	161306464
ENSE00003629276	161306108	161306168
ENSE00003643873	161306708	161306921

Expression profiles

Bgee: expression breadth ubiquitous, 178 present calls, max score 99.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.8498 / max 2128.2039, expressed in 1219 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
15636	5.5921	234
15631	1.5161	678
15635	1.5068	679
15632	0.1909	75
15633	0.0439	11

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibial nerve	UBERON:0001323	99.74	gold quality
sural nerve	UBERON:0015488	99.51	gold quality
olfactory bulb	UBERON:0002264	99.30	gold quality
trigeminal ganglion	UBERON:0001675	98.33	gold quality
dorsal root ganglion	UBERON:0000044	97.66	gold quality
lower esophagus muscularis layer	UBERON:0035833	85.36	gold quality
lower esophagus	UBERON:0013473	85.32	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	85.20	gold quality
muscle layer of sigmoid colon	UBERON:0035805	84.35	gold quality
left coronary artery	UBERON:0001626	83.28	gold quality
right atrium auricular region	UBERON:0006631	82.19	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.06	silver quality
coronary artery	UBERON:0001621	81.96	gold quality
cardiac atrium	UBERON:0002081	80.98	gold quality
seminal vesicle	UBERON:0000998	80.00	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	79.48	gold quality
sigmoid colon	UBERON:0001159	79.43	gold quality
colonic epithelium	UBERON:0000397	79.29	gold quality
hindlimb stylopod muscle	UBERON:0004252	78.84	gold quality
minor salivary gland	UBERON:0001830	78.41	gold quality
monocyte	CL:0000576	78.13	gold quality
skin of abdomen	UBERON:0001416	78.06	gold quality
left ventricle myocardium	UBERON:0006566	77.65	gold quality
esophagus	UBERON:0001043	77.64	gold quality
mononuclear cell	CL:0000842	77.63	gold quality
leukocyte	CL:0000738	77.30	gold quality
transverse colon	UBERON:0001157	76.80	gold quality
stromal cell of endometrium	CL:0002255	76.76	gold quality
left uterine tube	UBERON:0001303	76.73	gold quality
heart	UBERON:0000948	76.58	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-MTAB-8221	yes	1319.56
E-HCAD-56	yes	487.87
E-MTAB-10485	yes	405.93
E-HCAD-11	yes	34.93
E-MTAB-8410	yes	17.53
E-CURD-46	yes	13.61
E-ANND-3	no	1.73

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTCF, EGR2, ID1, JUN, MYC, PAX6, POU3F1, SOX10, ZNF699

miRNA regulators (miRDB)

132 targeting MPZ, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-223-3P	99.99	70.14	1140
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-6772-5P	99.94	67.01	577
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354

Literature-anchored findings (GeneRIF, showing 40)

• SSCP analysis for this gene in Croatian patients (PMID:12211648)
• We suggest that axonal and demyelinating forms of CMT are not two distinct classes, but rather parts of a spectrum of genotypically related conditions, particularly with some MPZ mutations (PMID:12911457)
• DNA sequencing analysis shows the Asn131Lys mutation in the myelin protein zero gene in three members of an affected family. (PMID:12940837)
• A novel mutation, Thr65Ala, in the MPZ gene in a patient with Charcot-Marie-Tooth type 1B disease with focally folded myelin. (PMID:15036333)
• Four missense mutations and one 4-base pair (bp) deletion, respectively, were identified in five patients, of which one mutation, c.173 T>A, has never been previously reported (PMID:15050444)
• MPZ gene screening should be performed for wide phenotype spectrum of Charcot-Marie-Tooth disease. (PMID:15094849)
• Chronic cough was associated with a Thr124 Met mutation. MPZ must be critical for maintenance of axonal function in addition to its role in myelin. All MPZ mutations associated with tonic pupils affect the same region of the extracellular domain. (PMID:15159512)
• A novel Thr124Lys mutation in the MPZ gene is associated with congenital neuropathy with hypomyelination. (PMID:15184631)
• Within 94 MPZ gene mutations reported up to now, only a few were identified in the exon 4 of the MPZ gene. In this study we have identified a novel Leu190fs mutation in the MPZ gene. (PMID:15261887)
• A novel mutation, 290 A–>T (Glu97Val), in the myelin protein zero gene (P0) is reported in a family with late-onset Charcot-Marie-Tooth disease type 2. (PMID:15326256)
• PMP22 and P0 are involved in both trans-homophilic and trans-heterophilic interactions. Disease-related point mutations of P0 resulted in a decreased adhesion capability correlating with the severity of the respective disease phenotype. (PMID:15555916)
• 4 patients had a Val102/fs null mutation (306delA at codon 102), age-dependent variability of clinical & electrophysiologic phenotype, segmental conduction abnormalities mainly in ulnar nerves at the elbow, & excessive myelin foldings & thickenings. (PMID:15596778)
• There was concordance between median MNCV and specific MPZ mutations. (PMID:15729519)
• P0, the major myelin protein, is also expressed during nephrogenesis and in mature kidney, mostly in podocytes. (PMID:16162811)
• family in which five members of three consecutive generations had a heterozygous mutation in nucleotide position 143 with a T-C transition in exon 2 of the MPZ gene. The resulting substitution of Leu48 with proline has not been previously described. (PMID:16198109)
• Charcot-Marie-Tooth disease due to the Thr124Met mutation in the myelin protein zero gene associated with multiple sclerosis. (PMID:16279991)
• Polymorphic short tandem repeats for PCR-based diagnosis of the Charcot-Marie-Tooth 1A duplication in Ukraine was performed. (PMID:16398147)
• Peripheral neuropathies caused by mutations in the myelin protein zero. (PMID:16414078)
• Two patients of Charcot-Marie-Tooth disease type 1B from subsequent generations were homozygous for an Asp195Tyr mutation in the intracellular domain of P0 (P0ic). (PMID:16488608)
• MPZ gene showed a novel point mutation in the extracellular domain in two families with axonal CMT. (PMID:16543539)
• Data confirm that a mutation in myelin protein zero can cause axonal neuropathy, in the absence of segmental demyelination, thus uncoupling the two pathological processes. (PMID:16856127)
• Intronic mutations cause CMT1B by disrupting splicing and certain MPZ mutations may cause neuropathy by interacting with the wild type MPZ in the extracellular space of compact myelin. (PMID:17030746)
• the cytoplasmic apposition (major dense line) in compact myelin may be stabilized via the hydrogen-bonding of beta-strands formed as a result of local P0-P0 aggregation. (PMID:17142269)
• a new myelin protein zero gene mutation (c.89T>C,Ile30Thr) was detected in a family with the Dejerine-Sottas disease phenotype (PMID:17143884)
• A patient with Charcot Marie Tooth Disease, Type Ib had a MPZ mutation with A-C transversion (nucleotide: 116, codon: 10, histidine-to-proline). (PMID:17602703)
• a novel Pro105Thr mutation in the MPZ gene (PMID:17663472)
• Congenital hypomyelinating neuropathy is a rare condition characterized by prenatal, neonatal or early infantile onset of hypotonia, paresis and areflexia.Here we describe a family with a heterozygous mutation in MPZ, confirmed in two generations. (PMID:17825553)
• In all patients, molecular analysis demonstrated a novel heterozygous missense mutation (208C>T) in MPZ exon 2, causing the Pro70Ser substitution in the extracellular domain. The diagnosis of CMT2 associated with MPZ (PMID:17940173)
• The novel mutation causes a late-onset demyelinating polyneuropathy, putatively resulting from aberrant intracellular trafficking of the mutant P(0) protein, which compromises the adhesiveness of the cells. (PMID:18209201)
• Results suggest that at least some late-onset MPZ mutations cause a partial loss of function in the transfected cells, whereas multiple abnormal gain of function pathways can result in early-onset neuropathy. (PMID:18337304)
• Our study provides further evidence that phenotypic features of MPZ mutations can vary within and among different families with CMT Ib (PMID:18422810)
• A heterozygous nonsense mutation (Tyr145Stop) corresponding to a T-to-A transition at nucleotide position 435 in exon 3 of the MPZ gene was identified in Charcot-Marie-Tooth disease type 1B patients. (PMID:18663734)
• Data show that the CMT1Adup, GJB1, MPZ and PMP22 mutation frequencies were in the range of those described in other CMT patient collectives with different ethnical backgrounds. (PMID:19259128)
• Findings suggest that the clinical features associated with MPZ mutations depend partly on the nature of amino acid change. (PMID:19293842)
• mutations in MPZ may have a role in Charcot-Marie-Tooth disease type 1B [case report] (PMID:19475438)
• The index patient of this family with unusual Charcot-Marie-Tooth phenotype is found to have a missense mutation within the intracellular domain of myelin protein zero. (PMID:19882637)
• Here we describe an unusual presentation of the Val102fs mutation characterized by symptoms of spinal root hypertrophy with no overt peroneal muscular atrophy. This report adds new data concerning the clinical presentations of MPZ mutations. (PMID:19906531)
• A genetic test disclosed a heterozygous mutation of myelin protein zero (MPZ); p.Thr124Met. (PMID:19928689)
• novel mutation in vocal cord paralysis (PMID:19950375)
• The results of this study concluded that ARG98HIS MPZ mutation may cause hereditary and relatively mild and asymmetric demyelinating sensorimotor polyneuropathy (PMID:20215982)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mpz	ENSDARG00000038609
mus_musculus	Mpz	ENSMUSG00000056569
rattus_norvegicus	Mpz	ENSRNOG00000003171

Paralogs (6): MPZL2 (ENSG00000149573), SCN2B (ENSG00000149575), MPZL3 (ENSG00000160588), JAML (ENSG00000160593), SCN4B (ENSG00000177098), MPZL1 (ENSG00000197965)

Protein

Protein identifiers

Myelin protein P0 — P25189 (reviewed: P25189)

Alternative names: Myelin peripheral protein, Myelin protein zero

All UniProt accessions (4): P25189, A0A0J9YWT2, A0A5F9ZI26, E9PL80

UniProt curated annotations — full annotation on UniProt →

Function. Is an adhesion molecule necessary for normal myelination in the peripheral nervous system. It mediates adhesion between adjacent myelin wraps and ultimately drives myelin compaction.

Subunit / interactions. Homodimer and homotetramer.

Subcellular location. Cell membrane Myelin membrane.

Tissue specificity. Found only in peripheral nervous system Schwann cells.

Post-translational modifications. N-glycosylated; contains sulfate-substituted glycan.

Disease relevance. Charcot-Marie-Tooth disease, demyelinating, type 1B (CMT1B) [MIM:118200] A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. The disease is caused by variants affecting the gene represented in this entry. Charcot-Marie-Tooth disease, axonal, type 2I (CMT2I) [MIM:607677] A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. The disease is caused by variants affecting the gene represented in this entry. Charcot-Marie-Tooth disease, axonal, type 2J (CMT2J) [MIM:607736] A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. Charcot-Marie-Tooth disease type 2J is characterized by the association of axonal peripheral neuropathy with hearing loss and pupillary abnormalities such as Adie pupil. The disease is caused by variants affecting the gene represented in this entry. Adie pupil (ADIEP) [MIM:103100] A stationary, benign disorder characterized by tonic, sluggishly reacting pupil and hypoactive or absent tendon reflexes. Adie pupil is a characteristic of Charcot-Marie-Tooth disease type 2J. The disease is caused by variants affecting the gene represented in this entry. Charcot-Marie-Tooth disease, dominant intermediate D (CMTDID) [MIM:607791] A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. The dominant intermediate type D is characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec. The disease may be caused by variants affecting the gene represented in this entry. Dejerine-Sottas syndrome (DSS) [MIM:145900] A severe degenerating neuropathy of the demyelinating Charcot-Marie-Tooth disease category, with onset by age 2 years. Characterized by motor and sensory neuropathy with very slow nerve conduction velocities, increased cerebrospinal fluid protein concentrations, hypertrophic nerve changes, delayed age of walking as well as areflexia. There are both autosomal dominant and autosomal recessive forms of Dejerine-Sottas syndrome. The disease is caused by variants affecting the gene represented in this entry. Roussy-Levy syndrome (ROULS) [MIM:180800] Autosomal dominant disorder that resembles Charcot-Marie-Tooth disease type 1 in that it presents with foot deformity, weakness and atrophy of distal limb muscles, especially the peronei, and absent tendon reflexes. The phenotype differs, however, in that it includes static tremor of the upper limbs and gait ataxia. The disease is caused by variants affecting the gene represented in this entry. Neuropathy, congenital hypomyelinating, 2 (CHN2) [MIM:618184] A form of congenital hypomyelinating neuropathy, a neurologic disorder characterized by early-onset hypotonia, areflexia, distal muscle weakness, and very slow nerve conduction velocities (NCV) resulting from improper myelination of axons. In its extreme form, it may present with severe joint contractures or arthrogryposis multiplex congenita and respiratory insufficiency. In less severe cases patients may achieve walking. Patients lack both active myelin breakdown and well-organized onion bulbs on sural nerve biopsies, have absence of inflammation, and show hypomyelination of most or all fibers. CHN2 inheritance is autosomal dominant. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. Based on a naturally occurring readthrough transcript. Highly antigenic.

Similarity. Belongs to the myelin P0 protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
P25189-1	1	yes
P25189-2	L-MPZ

RefSeq proteins (2): NP_000521, NP_001302420 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000920	Myelin_P0-rel	Family
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR019566	MYP0_C	Domain
IPR019738	Myelin_P0_CS	Conserved_site
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR047014	Myelin_P0_Ig-like	Domain

Pfam: PF07686, PF10570

UniProt features (121 total): sequence variant 91, strand 12, modified residue 5, helix 2, topological domain 2, signal peptide 1, chain 1, turn 1, glycosylation site 1, disulfide bond 1, splice variant 1, transmembrane region 1, domain 1, region of interest 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
8IIA	X-RAY DIFFRACTION	2.09
3OAI	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P25189-F1	82.38	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 233, 243, 210, 226, 228

Disulfide bonds (1): 50–127

Glycosylation sites (1): 122

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-9619665	EGR2 and SOX10-mediated initiation of Schwann cell myelination
R-HSA-1266738	Developmental Biology
R-HSA-9675108	Nervous system development

MSigDB gene sets: 283 (showing top): RNGTGGGC_UNKNOWN, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_CELL_CELL_SIGNALING, GOBP_CELL_CELL_ADHESION, MCBRYAN_PUBERTAL_BREAST_4_5WK_DN, GOBP_ENSHEATHMENT_OF_NEURONS, GOBP_CELL_AGGREGATION, MODULE_157, GOBP_SYNAPTIC_SIGNALING, LE_EGR2_TARGETS_DN, CTCAAGA_MIR526B, CAGCCTC_MIR4855P, KEGG_CELL_ADHESION_MOLECULES_CAMS, MODULE_104, GOCC_MYELIN_SHEATH

GO Biological Process (4): chemical synaptic transmission (GO:0007268), myelination (GO:0042552), obsolete cell-cell adhesion via plasma-membrane adhesion molecules (GO:0098742), cell aggregation (GO:0098743)

GO Molecular Function (1): structural molecule activity (GO:0005198)

GO Cellular Component (4): plasma membrane (GO:0005886), myelin sheath (GO:0043209), synapse (GO:0045202), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Nervous system development	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
anterograde trans-synaptic signaling	1
axon ensheathment	1
cellular process	1
molecular_function	1
membrane	1
cell periphery	1
cell junction	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

15 interactions, top by confidence:

A	B	Type	Score
FCGR2A	MPZ	psi-mi:“MI:0915”(physical association)	0.400
MPZ	IL6R	psi-mi:“MI:0915”(physical association)	0.400
IL6R	MPZ	psi-mi:“MI:0915”(physical association)	0.400
MPZ	ISLR2	psi-mi:“MI:0915”(physical association)	0.400
KIR2DL5A	MPZ	psi-mi:“MI:0915”(physical association)	0.400
LILRA5	MPZ	psi-mi:“MI:0915”(physical association)	0.400
LILRA6	MPZ	psi-mi:“MI:0915”(physical association)	0.400
LILRB3	MPZ	psi-mi:“MI:0915”(physical association)	0.400
LILRB5	MPZ	psi-mi:“MI:0915”(physical association)	0.400
SIGLEC6	MPZ	psi-mi:“MI:0915”(physical association)	0.400
CCP110	MPZ	psi-mi:“MI:0915”(physical association)	0.370
PSMB3	MPZ	psi-mi:“MI:0915”(physical association)	0.370
MRPS23	MYH7B	psi-mi:“MI:0914”(association)	0.350
MPZ	PINX1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (10): MPZ (Proximity Label-MS), MPZ (Synthetic Lethality), MPZ (Affinity Capture-Western), MPZ (Affinity Capture-MS), PMP22 (Affinity Capture-Western), MPZ (Affinity Capture-MS), MPZ (Proximity Label-MS), MPZ (Cross-Linking-MS (XL-MS)), MPZ (Affinity Capture-MS), PSMB3 (Two-hybrid)

ESM2 similar proteins: A0JM41, A2VD98, A6QQC6, A8MVW5, B0CLX4, B6ZK76, B6ZK77, O60487, O70255, O88324, O88775, O95976, P01832, P03228, P06907, P08920, P08921, P09619, P0C6B7, P0C6N0, P0CW72, P10522, P20938, P21995, P25189, P27573, P37301, P37998, P59823, P59824, P86176, Q01151, Q4VAH7, Q5EAB0, Q5R804, Q640U3, Q6PCB8, Q6WEB5, Q80UL9, Q86XK7

Diamond homologs: A0JM41, A2VD98, A5D7C3, O60487, O60939, O70255, O95297, P06907, P10522, P20938, P25189, P27573, P37301, P54900, Q29RR6, Q32PI9, Q3TEW6, Q3V3F6, Q4KLY3, Q5EAB0, Q5R804, Q6AYT8, Q6UWV2, Q6WEB5, Q7M729, Q7M730, Q86XK7, Q8AVM3, Q8IWT1, Q9D2J4, Q9PWR4, Q08E08, P78310, P97792, Q56A07, Q5R764, Q864L3, Q86YT9, Q8WMV3, Q91664

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
PMP22	“up-regulates activity”	MPZ	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 14 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	5	43.6×	4e-06
Adaptive Immune System	5	14.9×	4e-04

GO biological processes:

GO term	Partners	Fold	FDR
immune response-regulating signaling pathway	5	162.7×	5e-09
cytokine-mediated signaling pathway	5	46.7×	2e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

720 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	106
Likely pathogenic	57
Uncertain significance	328
Likely benign	101
Benign	12

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1045186	NM_000530.8(MPZ):c.437T>C (p.Val146Ala)	Pathogenic
1070661	NM_000530.8(MPZ):c.345del (p.His115fs)	Pathogenic
1070662	NM_000530.8(MPZ):c.171G>A (p.Trp57Ter)	Pathogenic
1076512	NM_000530.8(MPZ):c.638_639del (p.Gly213fs)	Pathogenic
1275760	NM_000530.8(MPZ):c.112del (p.Val38fs)	Pathogenic
14166	NM_000530.8(MPZ):c.286A>G (p.Lys96Glu)	Pathogenic
14167	NM_000530.8(MPZ):c.270C>A (p.Asp90Glu)	Pathogenic
14169	NM_000530.8(MPZ):c.188C>G (p.Ser63Cys)	Pathogenic
14170	NM_000530.8(MPZ):c.499G>C (p.Gly167Arg)	Pathogenic
14171	NM_000530.8(MPZ):c.646-7_647delinsGCAGGAGAG	Pathogenic
14175	NM_000530.8(MPZ):c.292C>T (p.Arg98Cys)	Pathogenic
14178	NM_000530.8(MPZ):c.643C>T (p.Gln215Ter)	Pathogenic
14179	NM_000530.8(MPZ):c.242A>G (p.His81Arg)	Pathogenic
14181	NM_000530.8(MPZ):c.371C>T (p.Thr124Met)	Pathogenic
14184	NM_000530.8(MPZ):c.224A>T (p.Asp75Val)	Pathogenic
14185	NM_000530.8(MPZ):c.131C>T (p.Ser44Phe)	Pathogenic
14186	NM_000530.8(MPZ):c.393C>A (p.Asn131Lys)	Pathogenic
14189	NM_000530.8(MPZ):c.184A>T (p.Ile62Phe)	Pathogenic
14191	NM_000530.8(MPZ):c.434A>C (p.Tyr145Ser)	Pathogenic
1419179	NM_000530.8(MPZ):c.323del (p.Lys108fs)	Pathogenic
14196	NM_000530.8(MPZ):c.371C>A (p.Thr124Lys)	Pathogenic
14200	NM_000530.8(MPZ):c.276G>A (p.Val92=)	Pathogenic
1423751	NM_000530.8(MPZ):c.424del (p.Val142fs)	Pathogenic
1449858	NM_000530.8(MPZ):c.571C>T (p.Gln191Ter)	Pathogenic
1685953	NM_000530.8(MPZ):c.401A>T (p.Asp134Val)	Pathogenic
1780739	NM_000530.8(MPZ):c.181dup (p.Asp61fs)	Pathogenic
1798896	NM_000530.8(MPZ):c.301dup (p.Trp101fs)	Pathogenic
2016722	NM_000530.8(MPZ):c.601A>T (p.Lys201Ter)	Pathogenic
2027108	NM_000530.8(MPZ):c.496del (p.Leu166fs)	Pathogenic
208146	NM_000530.8(MPZ):c.181G>A (p.Asp61Asn)	Pathogenic

SpliceAI

814 predictions. Top by Δscore:

Variant	Effect	Δscore
1:161306169:C:CC	acceptor_gain	1.0000
1:161306323:CCTTA:C	donor_loss	1.0000
1:161306324:CTTA:C	donor_loss	1.0000
1:161306325:TTA:T	donor_loss	1.0000
1:161306326:TA:T	donor_loss	1.0000
1:161306327:A:AG	donor_loss	1.0000
1:161306328:C:G	donor_loss	1.0000
1:161306460:TGGCA:T	acceptor_gain	1.0000
1:161306461:GGCA:G	acceptor_gain	1.0000
1:161306462:GCA:G	acceptor_gain	1.0000
1:161306463:CA:C	acceptor_gain	1.0000
1:161306463:CAC:C	acceptor_gain	1.0000
1:161306465:C:CC	acceptor_gain	1.0000
1:161306474:G:C	acceptor_gain	1.0000
1:161306474:G:GC	acceptor_gain	1.0000
1:161306723:A:AC	donor_gain	1.0000
1:161306724:C:CC	donor_gain	1.0000
1:161306724:CAG:C	donor_gain	1.0000
1:161307252:ACTC:A	donor_loss	1.0000
1:161307253:CTCA:C	donor_loss	1.0000
1:161307254:TCACC:T	donor_loss	1.0000
1:161307255:CACC:C	donor_loss	1.0000
1:161307256:A:AC	donor_gain	1.0000
1:161307256:ACCG:A	donor_loss	1.0000
1:161307257:C:CC	donor_gain	1.0000
1:161307257:CCGAA:C	donor_gain	1.0000
1:161307420:CAGCA:C	acceptor_gain	1.0000
1:161307421:AGCA:A	acceptor_gain	1.0000
1:161307422:GCA:G	acceptor_gain	1.0000
1:161307423:CA:C	acceptor_gain	1.0000

AlphaMissense

1598 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:161306763:G:C	N131K	1.000
1:161306763:G:T	N131K	1.000
1:161306775:A:C	C127W	1.000
1:161306776:C:G	C127S	1.000
1:161306776:C:T	C127Y	1.000
1:161306777:A:G	C127R	1.000
1:161306777:A:T	C127S	1.000
1:161306782:A:G	F125S	1.000
1:161306788:C:A	G123V	1.000
1:161306789:C:A	G123C	1.000
1:161306872:A:C	F95C	1.000
1:161307294:C:A	W66C	1.000
1:161307294:C:G	W66C	1.000
1:161307296:A:G	W66R	1.000
1:161307296:A:T	W66R	1.000
1:161307342:G:C	C50W	1.000
1:161307343:C:G	C50S	1.000
1:161307343:C:T	C50Y	1.000
1:161307344:A:G	C50R	1.000
1:161307344:A:T	C50S	1.000
1:161306719:A:T	V146D	0.999
1:161306725:A:G	L144P	0.999
1:161306766:T:A	K130N	0.999
1:161306766:T:G	K130N	0.999
1:161306770:A:T	V129D	0.999
1:161306776:C:A	C127F	0.999
1:161306781:G:C	F125L	0.999
1:161306781:G:T	F125L	0.999
1:161306782:A:C	F125C	0.999
1:161306783:A:G	F125L	0.999

dbSNP variants (sampled 300 via entrez): RS1000106583 (1:161309655 G>A), RS1000140979 (1:161308175 TAA>T), RS1001362325 (1:161303869 TA>T), RS1001647502 (1:161307559 C>G), RS1001783355 (1:161307922 A>G), RS1001973324 (1:161305695 A>C), RS1002263020 (1:161310111 G>T), RS1002476570 (1:161310402 CCT>C), RS1002599338 (1:161311571 G>A), RS1003036138 (1:161305750 C>G), RS1003040279 (1:161311412 G>C,T), RS1003532722 (1:161311353 T>C), RS1004304706 (1:161310137 G>A,C,T), RS1004678199 (1:161310447 T>C), RS1005267082 (1:161303102 C>A,T)

Disease associations

OMIM: gene MIM:159440 | disease phenotypes: MIM:118220, MIM:607791, MIM:118200, MIM:607677, MIM:180800, MIM:618184, MIM:145900, MIM:605253, MIM:607736, MIM:606482

GenCC curated gene-disease

Disease	Classification	Inheritance
Charcot-Marie-Tooth disease	Definitive	Autosomal dominant
Charcot-Marie-Tooth disease type 1B	Definitive	Autosomal dominant
neuropathy, congenital hypomyelinating, 2	Definitive	Autosomal dominant
Charcot-Marie-Tooth disease dominant intermediate D	Supportive	Autosomal dominant
autosomal dominant intermediate Charcot-Marie-Tooth disease with neuropathic pain	Supportive	Autosomal dominant
Charcot-Marie-Tooth disease type 3	Supportive	Autosomal dominant
Charcot-Marie-Tooth disease type 2I	Supportive	Autosomal dominant
Charcot-Marie-Tooth disease type 2J	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
Charcot-Marie-Tooth disease	Definitive	AD

Mondo (19): Charcot-Marie-Tooth disease (MONDO:0015626), Charcot-Marie-Tooth disease type 1 (MONDO:0019011), Charcot-Marie-Tooth disease dominant intermediate D (MONDO:0011909), Charcot-Marie-Tooth disease type 1B (MONDO:0007307), peripheral neuropathy (MONDO:0005244), Charcot-Marie-Tooth disease type 2I (MONDO:0011889), Roussy-Levy syndrome (MONDO:0008392), neuropathy, congenital hypomyelinating, 2 (MONDO:0020765), motor neuron disorder (MONDO:0020128), Charcot-Marie-Tooth disease type 3 (MONDO:0007790), Charcot-Marie-Tooth disease type 4E (MONDO:0011527), Charcot-Marie-Tooth disease type 2J (MONDO:0011903), sensory peripheral neuropathy (MONDO:0002321), distal hereditary motor neuropathy type 2 (MONDO:0015352), neuropathy, congenital hypomelinating (MONDO:0033352)

Orphanet (15): Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy (Orphanet:166), Charcot-Marie-Tooth disease type 1 (Orphanet:65753), Autosomal dominant intermediate Charcot-Marie-Tooth disease type D (Orphanet:100046), Charcot-Marie-Tooth disease type 1B (Orphanet:101082), Autosomal dominant Charcot-Marie-Tooth disease type 2I (Orphanet:99942), Roussy-Lévy syndrome (Orphanet:3115), Motor neuron disease (Orphanet:98503), Dejerine-Sottas syndrome (Orphanet:64748), Autosomal dominant Charcot-Marie-Tooth disease type 2J (Orphanet:99943), Charcot-Marie-Tooth disease type 4E (Orphanet:99951), Distal hereditary motor neuropathy type 2 (Orphanet:139525), Autosomal dominant intermediate Charcot-Marie-Tooth disease type B (Orphanet:100044), Autosomal dominant Charcot-Marie-Tooth disease type 2M (Orphanet:228179), Genetic motor neuron disease (Orphanet:98505), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

93 total (30 of 93 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000365	Hearing impairment
HP:0000407	Sensorineural hearing impairment
HP:0000408	Progressive sensorineural hearing impairment
HP:0000615	Abnormal pupil morphology
HP:0000639	Nystagmus
HP:0000762	Decreased nerve conduction velocity
HP:0001171	Split hand
HP:0001178	Ulnar claw
HP:0001252	Hypotonia
HP:0001265	Hyporeflexia
HP:0001270	Motor delay
HP:0001284	Areflexia
HP:0001288	Gait disturbance
HP:0001308	Tongue fasciculations
HP:0001324	Muscle weakness
HP:0001349	Facial diplegia
HP:0001558	Decreased fetal movement
HP:0001761	Pes cavus
HP:0001762	Talipes equinovarus
HP:0001763	Pes planus
HP:0001765	Hammertoe
HP:0002015	Dysphagia
HP:0002066	Gait ataxia
HP:0002070	Limb ataxia
HP:0002136	Broad-based gait
HP:0002174	Postural tremor
HP:0002312	Clumsiness
HP:0002317	Unsteady gait

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001523_16	Visceral adipose tissue adjusted for BMI	8.000000e-06
GCST008156_22	Hip circumference adjusted for BMI	4.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (7)

Descriptor	Name	Tree numbers
D002607	Charcot-Marie-Tooth Disease	C10.500.300.200; C10.574.500.495.200; C10.668.829.800.300.200; C16.131.666.300.200; C16.320.400.375.200
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D016472	Motor Neuron Disease	C10.574.562; C10.668.467
C564333	Charcot-Marie-Tooth Disease, Dominant Intermediate D (supp.)
C535417	Charcot-Marie-Tooth disease, Type 2J (supp.)
C535301	Charcot-Marie-Tooth disease, Type 4E (supp.)
C580044	Distal Hereditary Motor Neuropathy, Type II (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs12065184	MPZ		0.00	0

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	4
trichostatin A	affects cotreatment, increases expression	3
Resveratrol	affects cotreatment, increases expression, decreases expression	2
Panobinostat	affects cotreatment, increases expression	2
Nickel	decreases expression	2
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	increases expression	1
ferrous chloride	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Arsenic Trioxide	increases expression	1
Vorinostat	affects cotreatment, increases expression	1
Acetaminophen	decreases expression	1
Carbamazepine	affects expression	1
Cisplatin	increases expression	1
Copper	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Lipopolysaccharides	affects response to substance, increases expression	1
N-Nitrosopyrrolidine	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Quercetin	increases expression	1
Thiram	increases expression	1

Cellosaurus cell lines

12 cell lines: 8 induced pluripotent stem cell, 3 transformed cell line, 1 finite cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1K24	GM05148	Finite cell line	Male
CVCL_1K25	GM05149	Transformed cell line	Male
CVCL_B0IG	GM28252	Induced pluripotent stem cell	Male
CVCL_JW96	NYSCF-AG0003-01-MR	Induced pluripotent stem cell	Female
CVCL_JW98	NYSCF-AG0007-01-MR	Induced pluripotent stem cell	Male
CVCL_JX00	NYSCF-AG0009-02-MR	Induced pluripotent stem cell	Male
CVCL_JX10	NYSCF-AG0019-01-MR	Induced pluripotent stem cell	Male
CVCL_M916	GM23721	Transformed cell line	Female
CVCL_QX72	KUCFRi002-A	Induced pluripotent stem cell	Female
CVCL_RZ99	NYSCF-AG0001-01-MR	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

299 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00380965	PHASE4	COMPLETED	Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy
NCT00487981	PHASE4	TERMINATED	Spinal Cord Stimulation for Painful Diabetic Neuropathy
NCT00904202	PHASE4	COMPLETED	A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
NCT01192113	PHASE4	COMPLETED	Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109)
NCT01373983	PHASE4	COMPLETED	Intrathecal Bolus Doses of Ziconotide
NCT01458015	PHASE4	TERMINATED	Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain
NCT02074267	PHASE4	COMPLETED	Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain
NCT02372149	PHASE4	UNKNOWN	IVIg for Demyelination in Diabetes Mellitus
NCT02670161	PHASE4	ENROLLING_BY_INVITATION	Quality Improvement and Practice Based Research in Neurology Using the EMR
NCT07022938	PHASE4	COMPLETED	Nutritional Supplement for Treating Chemotherapy Induced Neuropathy
NCT07025005	PHASE4	RECRUITING	Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
NCT04762758	PHASE3	UNKNOWN	Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients
NCT00058071	PHASE3	COMPLETED	Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
NCT00125268	PHASE3	TERMINATED	Near Infrared Light for the Treatment of Painful Peripheral Neuropathy
NCT00195013	PHASE3	COMPLETED	Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy
NCT00232141	PHASE3	COMPLETED	Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy
NCT00264875	PHASE3	COMPLETED	Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
NCT00369564	PHASE3	COMPLETED	Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
NCT00471445	PHASE3	COMPLETED	Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
NCT00489411	PHASE3	COMPLETED	Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
NCT00710554	PHASE3	COMPLETED	A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia
NCT00711880	PHASE3	COMPLETED	A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.
NCT00713323	PHASE3	COMPLETED	A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.
NCT00713817	PHASE3	COMPLETED	A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain
NCT00775645	PHASE3	COMPLETED	S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
NCT00872352	PHASE3	UNKNOWN	Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients
NCT00998738	PHASE3	TERMINATED	Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
NCT01049217	PHASE3	TERMINATED	Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy
NCT01099449	PHASE3	COMPLETED	Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
NCT01288937	PHASE3	TERMINATED	A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
NCT01492920	PHASE3	WITHDRAWN	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
NCT01775449	PHASE3	COMPLETED	Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet
NCT02024191	PHASE3	UNKNOWN	The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy
NCT02217267	PHASE3	COMPLETED	Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain
NCT02294149	PHASE3	UNKNOWN	Vit D3 and Omega 3 in Chemo Induced Neuropathy
NCT02311907	PHASE3	COMPLETED	Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
NCT06071936	PHASE3	UNKNOWN	Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
NCT06071975	PHASE3	UNKNOWN	Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
NCT06071988	PHASE3	UNKNOWN	Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
NCT06072573	PHASE3	UNKNOWN	Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy